U.S. FDA approves first mRNA flu shot from Moderna
分析失败
The shot, mFlusiva, was given a traditional approval for adults aged 50 to 64, and an accelerated approval for those 65 years and older.
LISA · 延伸对话
与 Lisa 深入探讨这篇报告
基于本报告上下文的延伸分析
The shot, mFlusiva, was given a traditional approval for adults aged 50 to 64, and an accelerated approval for those 65 years and older.
基于本报告上下文的延伸分析